EMA Authorised: Neparvis (sacubitril;valsartan) — Novartis Europharm Limited

View source ↗

Summary

Neparvis, a sacubitril/valsartan combination, has been authorised by the EMA for heart failure. The marketing authorization holder is Novartis Europharm Limited…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Neparvis (sacubitril/valsartan)

Snippet

Status: Authorised. Therapeutic area: Heart Failure. MAH: Novartis Europharm Limited. Decision date: 12/01/2026